Antonella Giampietro
Overview
Explore the profile of Antonella Giampietro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Costanza F, Cicia M, Giampietro A, Tartaglione T, Angelini F, Zoli A, et al.
Endocr Metab Immune Disord Drug Targets
. 2024 Jul;
PMID: 39082174
Introduction: Hypophysitis is an inflammatory disorder of the pituitary gland. It can manifest variously, with endocrinological and neuro-ophthalmologic symptoms and signs, due to the compression of sellar and parasellar structures....
12.
Costanza F, Giampietro A, Tartaglione T, Angelini F, Gaudino S, De Marinis L, et al.
Endocr Metab Immune Disord Drug Targets
. 2024 Jul;
PMID: 38982704
Background: Hypophysitis is a rare inflammatory disorder of the pituitary gland. Symptoms and signs of hypophysitis can be various, and its recognition may be challenging. Arginine vasopressin deficiency (AVP-D) due...
13.
Costanza F, Chiloiro S, Giampietro A, Angelini F, Infante A, Pontecorvi A, et al.
Endocr Metab Immune Disord Drug Targets
. 2024 Jul;
PMID: 38982703
Background: Acromegaly is associated with skeletal fragility and increased prevalence of vertebral fractures (VF). Two isoforms of GH receptor (GHR) have been described, which differ in the presence or absence...
14.
Veleno M, Giampietro A, Raia S, Menotti S, Tartaglione T, Gaudino S, et al.
Minerva Endocrinol (Torino)
. 2024 Jul;
49(3):269-282.
PMID: 38963295
The review explores the 2022 update to the World Health Organization (WHO) classification of pituitary adenomas, now referred to as pituitary neuroendocrine tumors (PitNETs), and his possible impact on the...
15.
Chiloiro S, Appetecchia M, Bianchi A, Costa D, De Acetis C, Gargiulo P, et al.
Drugs Context
. 2024 May;
13.
PMID: 38817802
Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the...
16.
Chiloiro S, Giampietro A, Infante A, Mattogno P, Lauretti L, Olivi A, et al.
Pituitary
. 2024 May;
27(3):303-309.
PMID: 38713317
Introduction: Skeletal fragility is a clinically relevant and not-reversible complication of acromegaly, involving around 30-40% of patients since the disease diagnosis. Few studies have investigated the effects on skeletal health...
17.
Chiloiro S, Capoluongo E, Costanza F, Minucci A, Giampietro A, Infante A, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38339173
Several genetic investigations were conducted to identify germline and somatic mutations in somatotropinomas, a subtype of pituitary tumors. To our knowledge, we report the first acromegaly patient carrying a pathogenic...
18.
Calandrelli R, Mattogno P, Chiloiro S, Gessi M, DApolito G, Tartaglione T, et al.
Diagnostics (Basel)
. 2024 Feb;
14(3).
PMID: 38337790
Background: We aim to assess the role of a multidisciplinary approach in pituitary adenomas (PitNETs) classification, evaluate criteria concordance, and compare intraoperative assessments with post-operative MRIs for tumor remnants. Methods:...
19.
Raia S, Chiloiro S, Giampietro A, Maratta M, Attili F, Brizi M, et al.
Endocr Metab Immune Disord Drug Targets
. 2024 Jan;
24(12):1464-1469.
PMID: 38284724
Background: Pancreatic metastases from medullary thyroid carcinoma (MTC) are exceptional. Imaging and treatment based on somatostatin receptors may play a role, though the evidence is unconvincing. Case Presentation: We have,...
20.
Giampietro A, Chiloiro S, Urbani C, Pivonello R, Carlsson M, Dassie F, et al.
Endocr Connect
. 2024 Jan;
13(3).
PMID: 38197875
Purpose: The aim of this study was to examine the probability of achieving acromegaly disease control according to several patient-, disease- and treatment-related factors longitudinally. Methods: We analyzed data from...